IMO, JMAR has two major problems. The first and most important is that they have no money. It takes money to keep operating, pay salaries, suppliers, and all that mundane stuff. The undercapitalization may well force them into bankruptcy, even though their technology should be worth a lot more than the market to somebody.
The second problem is no PR coming out from them on the progress of their Biosentry product line, in the various trials going on with water applications, the utilities, cruise ships, beverage mfg, etc. One can only assume that whatever news exists there is not good, else it would be released. In this case, my guess is that no news is not good news. |
